首页 > 市场调查报告书 > 製药

以基因为基之药物开发

市场调查报告书

商品编码

1532475

药物基因组学市场规模 - 按产品、技术、应用、疾病领域、最终用户和预测划分，2024 年 - 2032 年

Pharmacogenomics Market Size - By Offering, Technology, Application, Disease Area, End-user & Forecast, 2024 - 2032

出版日期: 2024年05月17日 | 出版商:

Global Market Insights Inc. | 英文 228 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于产品推出数量不断增加、技术进步以及降低医疗保健成本的努力，预计 2024 年至 2032 年全球药物基因组学市场规模的复合年增长率将超过 10.5%。这些因素正在推动遗传讯息融入药物开发和个人化医疗。

药物基因组学也用于透过利用新技术提供有效的护理并为更有针对性的治疗提供有价值的见解来提高治疗的精确度并改善患者的治疗结果。例如，2022 年 12 月，MapmyGenome 推出了 MedicaMap，这是一种价格实惠的药物基因组学解决方案，涵盖超过 165 种药物，以增强个人化医疗，从而深入了解个人对各种药物的反应。

市场分为产品、技术、应用、疾病领域、最终用户和地区。

在服务方面，预计到 2032 年，药物基因组学行业的服务领域将经历显着的增长。医疗保健提供者目前也透过使用这项服务，根据患者独特的基因图谱确定最有效的治疗方法。

从应用来看，临床研究领域的药物基因组学市场预计将在 2024 年至 2032 年期间成长，这得益于越来越多的采用根据个体基因图谱定製药物疗法。研究人员正在研究遗传变异如何影响药物代谢和功效，以增强个人化医疗方法。随着基因检测和资料分析的进步，药物治疗精确度的提高正在导致更有针对性和更有效的治疗计划的发展。

从地区来看，在慢性病发病率上升以及个人化医疗意识和采用不断提高的推动下，亚太地区药物基因组学行业规模预计将在 2024 年至 2032 年间增长。研究人员和医疗保健提供者正在将药物基因组学纳入治疗计划，以更好地满足糖尿病和心臟病等慢性病患者的需求，从而促进区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 增加研发投入
  - 癌症盛行率增加
  - 越来越多采用精准医疗方法
  - 药物不良反应负担增加
- 产业陷阱与挑战
  - 成本和报销挑战
  - 遗传资料的复杂性与解释
成长潜力分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按产品分类，2021 - 2032 年

主要趋势
试剂盒和试剂
- 定序试剂盒和试剂
- PCR 试剂盒和试剂
- 微阵列试剂盒和试剂
- 其他试剂盒和试剂
服务

第 6 章：市场估计与预测：按技术划分，2021 - 2032 年

主要趋势
定序
聚合酶炼式反应
微阵列
其他技术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
个人化医疗
临床研究
药物发现与临床前开发

第 8 章：市场估计与预测：按疾病领域，2021 - 2032

主要趋势
肿瘤学
心血管疾病
神经系统疾病
传染病
心理健康
其他疾病领域

第 9 章：市场估计与预测：按最终用户分类，2021 - 2032 年

主要趋势
医院和诊所
学术及研究机构
製药和生物技术公司
合约研究组织

第 10 章：市场估计与预测：按地区划分，2021 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 11 章：公司简介

Agilent Technologies Inc.
Becton, Dickinson and Company
Bio-Rad Laboratories Inc.
Charles River Laboratories
Danaher Corporation
Eurofins Scientific
F. Hoffmann-La Roche Ltd
Illumina Inc.
Laboratory Corporation of America Holdings
Mesa Labs, Inc.
Novogene Co., Ltd.
Revvity
Qiagen N.V.
Takara Bio Inc.
Thermo Fisher Scientific Inc.

简介目录

Product Code: 9535

Global Pharmacogenomics Market size is anticipated to record over 10.5% CAGR from 2024 to 2032, due to increasing number of product launches, technological advancements, and efforts to reduce healthcare costs. These factors are driving the amalgamation of genetic information into drug development and personalized medicine.

Pharmacogenomics are also used for enhancing the precision of treatments and improving patient outcomes by leveraging new technologies for delivering effective care and providing valuable insights for more targeted therapies. For instance, in December 2022, MapmyGenome launched MedicaMap, an affordable pharmacogenomics solution covering over 165 drugs to enhance personalized medicine for providing insights into how individuals respond to various medications.

The market is segregated into offering, technology, application, disease area, end-user, and region.

In terms of offering, the service segment in the pharmacogenomics industry is predicted to experience significant growth rate through 2032. Pharmacogenomics are transforming the way medications are prescribed by analyzing how genetic makeups of individuals are affecting their responses to drugs. Healthcare providers are also currently identifying the most effective treatments for patients based on their unique genetic profiles by using this service.

By application, the pharmacogenomics market from the clinical research segment is expected to rise from 2024 to 2032, fueled by increasing adoption to tailor drug therapies to individual genetic profiles. Researchers are studying how genetic variations impact drug metabolism and efficacy for enhancing the personalized medicine approaches. With advancements in genetic testing and data analysis, the improvements in precision of drug therapies is leading to the development of more targeted and effective treatment plans.

Regionally, the Asia Pacific pharmacogenomics industry size is expected to grow between 2024 and 2032, propelled by the rising incidence of chronic diseases along with increasing awareness and adoption of personalized medicine. Researchers and healthcare providers are integrating pharmacogenomics into treatment plans to better address the needs of patients with chronic conditions, such as diabetes and heart disease, adding to the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360°synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing research and development investments
  - 3.2.1.2 Increasing prevalence of cancer
  - 3.2.1.3 Increasing adoption of precision medicine approaches
  - 3.2.1.4 Rising burden of adverse drug reactions
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Cost and reimbursement challenges
  - 3.2.2.2 Complexity and interpretation of genetic data
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Offering, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Kits & reagents
- 5.2.1 Sequencing kits & reagents
- 5.2.2 PCR kits & reagents
- 5.2.3 Microarray kits & reagents
- 5.2.4 Other kits & reagents
5.3 Service

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Sequencing
6.3 PCR
6.4 Microarray
6.5 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Personalized medicine
7.3 Clinical research
7.4 Drug discovery and preclinical development

Chapter 8 Market Estimates and Forecast, By Disease Area, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oncology
8.3 Cardiovascular disorders
8.4 Neurological diseases
8.5 Infectious diseases
8.6 Mental health
8.7 Other disease areas

Chapter 9 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospitals & clinics
9.3 Academic & research institutes
9.4 Pharmaceutical & biotechnology companies
9.5 CROs

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa